Sigyn Therapeutics, Inc. (SIGY)
Oxford Ledge is still expanding full research coverage of SIGY. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Sigyn Therapeutics develops blood purification devices to treat infectious diseases and optimize cancer drug performance.
Source: 10-K (2024-12-31) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- 8-K Entry into material agreement; 3.02; Financial statements and exhibits 2026-02-20
- 10-Q Quarterly financial report (unaudited) 2025-11-14
- 10-Q Quarterly financial report (unaudited) 2025-09-05
- 8-K Entry into material agreement; 3.02; Departure/election of directors or officers; Other material event; Financial statements and exhibits 2025-08-15
- 10-Q Quarterly financial report (unaudited) 2025-05-20
Source: SEC EDGAR.
Annual results
5 years of annual figures for SIGY, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2024 | — | -$3.3M | -$2.51 |
| 2023 | — | -$4.1M | -$3.77 |
| 2022 | — | -$2.9M | -$3.13 |
| 2021 | — | -$3.0M | — |
| 2020 | — | -$1.3M | — |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
- Open SIGY in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.